Cargando…

Colchicine-Induced Hepatotoxicity

Drug-induced injury (DILI) is a frequent cause of abnormal liver tests and a leading cause of liver failure in the United States. Colchicine has long been used as a systemic anti-inflammatory agent for treatment of gout by inhibiting mitotic activity and neutrophil function. We present the first cas...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbott, Collette E., Xu, Ruliang, Sigal, Samuel H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Gastroenterology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703762/
https://www.ncbi.nlm.nih.gov/pubmed/29201931
http://dx.doi.org/10.14309/crj.2017.120
_version_ 1783281745405149184
author Abbott, Collette E.
Xu, Ruliang
Sigal, Samuel H.
author_facet Abbott, Collette E.
Xu, Ruliang
Sigal, Samuel H.
author_sort Abbott, Collette E.
collection PubMed
description Drug-induced injury (DILI) is a frequent cause of abnormal liver tests and a leading cause of liver failure in the United States. Colchicine has long been used as a systemic anti-inflammatory agent for treatment of gout by inhibiting mitotic activity and neutrophil function. We present the first case of colchicine-induced hepatoxicity, supported by histopathologic findings characteristic of colchicine-induced injury and resolution of liver enzyme abnormalities after its discontinuation. Colchicine-associated DILI has implications for the evaluation of patients with abnormal liver tests and gout, especially for patients with alcoholism and non-alcoholic fatty liver disease, in whom there is an increased incidence of gout.
format Online
Article
Text
id pubmed-5703762
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American College of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-57037622017-11-30 Colchicine-Induced Hepatotoxicity Abbott, Collette E. Xu, Ruliang Sigal, Samuel H. ACG Case Rep J Case Report Drug-induced injury (DILI) is a frequent cause of abnormal liver tests and a leading cause of liver failure in the United States. Colchicine has long been used as a systemic anti-inflammatory agent for treatment of gout by inhibiting mitotic activity and neutrophil function. We present the first case of colchicine-induced hepatoxicity, supported by histopathologic findings characteristic of colchicine-induced injury and resolution of liver enzyme abnormalities after its discontinuation. Colchicine-associated DILI has implications for the evaluation of patients with abnormal liver tests and gout, especially for patients with alcoholism and non-alcoholic fatty liver disease, in whom there is an increased incidence of gout. American College of Gastroenterology 2017-11-22 /pmc/articles/PMC5703762/ /pubmed/29201931 http://dx.doi.org/10.14309/crj.2017.120 Text en Copyright © Abbott et al. This is an open-access article. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Case Report
Abbott, Collette E.
Xu, Ruliang
Sigal, Samuel H.
Colchicine-Induced Hepatotoxicity
title Colchicine-Induced Hepatotoxicity
title_full Colchicine-Induced Hepatotoxicity
title_fullStr Colchicine-Induced Hepatotoxicity
title_full_unstemmed Colchicine-Induced Hepatotoxicity
title_short Colchicine-Induced Hepatotoxicity
title_sort colchicine-induced hepatotoxicity
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703762/
https://www.ncbi.nlm.nih.gov/pubmed/29201931
http://dx.doi.org/10.14309/crj.2017.120
work_keys_str_mv AT abbottcollettee colchicineinducedhepatotoxicity
AT xuruliang colchicineinducedhepatotoxicity
AT sigalsamuelh colchicineinducedhepatotoxicity